Enrolling Studies

Adapt
Medtronic
A prospective, randomized, controlled, interventional, single-blinded, multi-center, post-market, global cardiac resynchronization therapy (CRT) in heart failure (HF) clinical study.

CardioMEMS
Abbott
Post-approval study is to provide safety and effectiveness data regarding the use of the CardioMEMS HF System in a commercial setting.

Crest2  
NINDS
Carotid revascularization and medical management for asymptomatic carotid stenosis trial.

DalGene
DalCor Pharma UK

Define HF
A 12-week randomized, double-blind, placebo-controlled trial to evaluate the effects of once-daily dapagliflozin 10 mg on heart failure disease-specific biomarkers (BNP and NTproBNP), symptoms, health status, and quality of life in patients with type 2 diabetes and chronic heart failure with reduced systolic function.

Gould
Amgen
Getting to an improved understanding of low-density lipoprotein cholesterol and dyslipidemia management (GOULD): a registry of high cardiovascular risk subjects in the United States.

Intervene HF
Medtronic
Integrated diagnostics driven diuretic and chronic medication management for heart failure (INTERVENE-HF), a prospective, nonrandomized, multicenter, feasibility study.

Voyager
Bayer HeathCare
An international, multicenter, randomized, double-blind, placebo controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures.

Pioneer HF
Novartis
A multicenter, randomized, double-blind, double dummy, parallel group, active-controlled 8-week study to evaluate the effect of sacubitril and valsartan (LCZ696) versus enalapril on changes in NT-proBNP and safety and tolerability of in-hospital initiation of LCZ696 compared to enalapril in HFrEF patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF).

Reveal
Rex Medical
A single-arm study of the Revolution™ Peripheral Atherectomy System in subjects with peripheral arterial disease (PAD).